LUMENS BIOS CO. LTD.

LUMENS BIOS CO. LTD.

KKRX:038060
1,066.00
KRW
-29.00
(-2.65%)
-209.03EPS
35.02BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
28,701.47
22,780.36
18,587.15
17,671.75
15,893.19
14,170.66
14,015.21
8,806.21
7,329.57
7,075.15
7,267.96
7,295.18
7,283.99
6,896.42
Basic EPS, GAAP
1,524
510
-266
-234
138
-1,382
-2,682
-748
-1,164
676
170
370
-276
-209.03
Free Cash Flow per Basic Share
3,505.26
-524.64
429.21
-421.08
-759.71
-998.5
-294.79
14.21
-478.92
-1,006.32
821.42
66.57
506.71
-40.77
Dividend per Share
- -
- -
49.9
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
9,343.86
9,946.12
9,696.1
9,492.88
9,189.51
7,752.79
5,080.49
4,078.43
3,135.52
3,984.55
4,160.1
4,633.36
4,404.58
4,559.85
Tangible Book Value per Share
9,053.35
9,667.48
9,518.12
9,299
8,714.03
7,250.2
4,535.87
3,754.62
3,111.15
3,925.72
4,023.58
4,514.86
4,329.28
4,486.55
Basic Weighted Avg Shares
21
23
23
23
23
23
23
23
24
24
24
24
24
24
Sales/Revenue/Turnover
614,155
524,481
425,616
402,841
361,567
325,835
323,588
205,251
172,339
166,305
171,237
174,228
175,538
165,870
Operating Margin (%)
8.55
3.83
1.44
1.3
-2.55
-6.26
-11.82
-0.4
-0.87
2.5
1.84
-0.87
-2.5
-2.91
Depreciation Expense
29,133
23,145
18,264
20,322
19,295
21,335
20,073
13,511
7,570
3,715
3,166
3,423
3,919
3,792
Net Income, GAAP
32,611
11,742
-6,091
-5,334
3,139
-31,777
-61,923
-17,434
-27,369
15,890
4,005
8,837
-6,651
-5,027
Effective Tax Rate (%)
21.38
26.83
- -
- -
- -
- -
- -
- -
- -
3.29
21.07
14.16
- -
- -
Profit Margin (%)
5.31
2.24
-1.43
-1.32
0.87
-9.75
-19.14
-8.49
-15.88
9.55
2.34
5.07
-3.79
-3.03
Working Capital
96,128
121,774
107,182
87,856
75,826
57,491
14,319
2,617
60,460
82,699
76,557
84,028
83,401
87,809
LT Debt
9,300
11,750
17,500
23,264
19,037
18,635
9,674
6,675
1,024
796
489
801
742
558
Total Equity
207,319
229,319
219,292
213,859
222,073
191,427
130,557
97,481
73,783
93,677
97,804
111,439
105,937
109,671
Return on Invested Capital (%)
17.59
5.82
- -
- -
- -
- -
- -
- -
- -
1.11
2.08
-1.27
- -
- -
Return on Capital (%)
15.04
5.02
- -
- -
- -
- -
- -
- -
- -
15.83
4.27
8.1
- -
- -
Return on Common Equity (%)
18.25
5.4
-2.71
-2.43
1.47
-16.34
-41.78
-16.41
-32.42
18.98
4.18
8.45
-6.12
-4.53

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
782
726
505
LT Borrowings
- -
- -
- -
LT Finance Leases
829
742
558
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
35,692
29,487
35,019

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
121,035
123,727
119,767
Cash, Cash Equivalents & STI
53,164
59,696
57,987
Accounts Receivable, Net
29,461
28,228
25,222
Inventories
26,308
24,129
24,506
Total Current Liabilities
35,831
40,326
31,959
Payables & Accruals
- -
- -
- -
ST Debt
782
726
505
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.35%
3.21%
-4.94%
Free Cash Flow
-325.45%
-598.9%
668.02%
Net Income, GAAP
-149.09%
-46.1%
-175.27%
Sales/Revenue/Turnover
-7.68%
-2.81%
0.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39,187
41,676
47,966
45,399
174,228
2025
47,904
36,720
44,401
46,513
175,538
2026
38,235
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
134
58
20
158.92
370
2025
28
-211.41
-5.77
-88.27
-276
2026
96.42
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yoon-Min Park
Full Time Employees
92
Sector
Electronic technology
Industry
Semiconductors
Address
Yongin-si South Korea
IPO Date
Aug 8, 2006
Business
Lumens Bios Co., Ltd. is a South Korea-based optical semiconductor and biotechnology company primarily engaged in the research, development, manufacture, and commercialization of advanced light-emitting diode (LED) packages, optical display modules, micro-LED displays, and bio-photonic solutions. Founded in 1996 and headquartered in Yongin-si, Gyeonggi-do, South Korea, the company operates across display components, automotive electronics, specialty illumination, and life sciences business segments, supplying original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, automotive Tier-1 suppliers, and commercial enterprises across South Korea, Greater China, Southeast Asia, North America, and Europe. The company's primary products and services are structured into comprehensive technology categories: display LED solutions, including LED backlight units (BLUs) and light bars for ultra-high-definition (UHD) televisions, desktop monitors, notebook computers, and tablet devices; next-generation micro-LED and mini-LED modules, featuring fine-pitch micro-LED panels for commercial digital signage, smart glass optical engines, augmented reality (AR) micro-displays, and automotive head-up display (HUD) units; automotive lighting systems, encompassing exterior forward lighting, daytime running lights (DRLs), rear combination lamps (RCLs), turn indicators, center high-mounted stop lamps (CHMSLs), and interior ambient mood lighting; specialty and general lighting, comprising high-efficiency commercial and industrial luminaire modules, street lamps, architectural floodlights, and ultraviolet (UV-A, UV-C) LED systems designed for surface sterilization, water purification, and industrial curing applications; and bio-photonic healthcare solutions, which provide optical biosensors, optical diagnostic devices, phototherapeutic wellness instruments, and biomedical illumination modules. In recent developments, the company executed a strategic corporate reorganization and name change to Lumens Bios Co., Ltd., marking a major strategic transition from legacy consumer display backlight components toward high-value bio-photonics, medical technologies, and advanced micro-display applications. In alignment with this strategic transformation, the company restructured its production footprint by rationalizing lower-margin standard LED manufacturing lines and reallocating capital resources toward micro-LED cleanroom capacity and biosensor R&D facilities. Additionally, the company has forged strategic technological partnerships and joint development initiatives with life science institutions and mobility component manufacturers to accelerate the commercialization of point-of-care optical diagnostics and automotive smart surface displays, supported by capital management initiatives to enhance operational liquidity and fund ongoing product diversification.